TBCRC 048 (Olaparib Expanded) Expansion Cohorts: Phase II Study of Olaparib Monotherapy for Patients With Metastatic Breast Cancer With Germline Mutations in PALB2 or Somatic Mutations in BRCA1 or BRCA2

医学 奥拉帕尼 转移性乳腺癌 内科学 生殖系 肿瘤科 种系突变 乳腺癌 体细胞 临床研究阶段 PARP抑制剂 人口 癌症 聚ADP核糖聚合酶 突变 癌症研究 总体生存率 BRCA突变 转移 PALB2
作者
Nadine Tung,Mark E. Robson,Tianyu Li,Rita Nanda,Payal Deepak Shah,Katia E. Khoury,Gretchen Genevieve Kimmick,Cesar Augusto Santa-Maria,Adam Brufsky,Michelle K. DeMeo,Joao Pedro Vieira,LA Carey,Gerburg M. Wulf,Susan Domchek,Ian E. Krop,Antonio C. Wolff,Eric P. Winer,Judy Ellen Garber
出处
期刊:Journal of Clinical Oncology [Lippincott Williams & Wilkins]
卷期号:44 (8): 653-661 被引量:30
标识
DOI:10.1200/jco-25-02075
摘要

PURPOSE Translational Breast Cancer Research Consortium 048 was a proof-of-principle trial demonstrating responses to the poly (ADP-ribose) polymerase (PARP) inhibitor olaparib in patients (pts) with metastatic breast cancer (MBC) with germline (g) PALB2 or somatic (s) BRCA mutations (s BRCA m). Here we report results from the expansion cohorts in a larger sample of pts with g PALB2 m or s BRCA m. METHODS Eligible pts had MBC of any subtype with measurable disease and a g PALB2 m or s BRCA m. Pts received olaparib 300 mg twice a day until progression. The primary end point was overall response rate. Secondary end points include clinical benefit rate (CBR) at 18 weeks, progression-free survival (PFS), duration of response (DOR), and whether among s BRCA m carriers the mutant allele frequency (MAF) is significantly higher in responders than in nonresponders. RESULTS Fifty-four pts with g PALB2 m (N = 24) or s BRCA m (N = 30) were enrolled. Forty-two (78%) had estrogen receptor–positive human epidermal growth factor receptor 2–negative (HER2–) MBC, seven (13%) had triple-negative breast cancer, and five (9%) had HER2+ disease. Among pts with a g PALB2 m, the overall response rate (ORR) was 75% (80% CI, 60.2 to 86.3), CBR was 83.3% (90% CI, 65.8 to 94.1), the median PFS was 9.4 months (90% CI, 8.3 to 13.1), and the median DOR was 7.0 months (90% CI, 5.6 to 10.4). Among pts with s BRCA m (15 s BRCA1 and 15 s BRCA2 ), the ORR was 36.7% (80% CI, 24.7 to 50), CBR was 53.3% (90% CI, 37 to 69.1), the median PFS was 5.5 months (90% CI, 2.8 to 8.3), and the median DOR was 11.2 months (90% CI, 4.4 to not reached). One additional pt had an unconfirmed partial response. Although clinically meaningful, the ORR in pts with s BRCA m did not achieve the prespecified target. Among s BRCA m carriers, the mean MAF did not differ significantly between responders (46%) and nonresponders (39%; P = .7). CONCLUSION Olaparib is active in pts with MBC with g PALB2 m and s BRCA m, significantly expanding the population of pts with breast cancer likely to benefit from PARP inhibitors beyond g BRCA1/2 m carriers.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
湖蓝色块完成签到 ,获得积分10
刚刚
大胆初南完成签到 ,获得积分10
1秒前
1秒前
YK完成签到,获得积分10
1秒前
喷火娃的应助被炙热的诗蕾采纳,获得10
1秒前
molihuakai的应助被炙热的诗蕾采纳,获得10
1秒前
刘澜旭发布了新的文献求助10
2秒前
2秒前
3秒前
本色风情发布了新的文献求助10
3秒前
4秒前
lllll1243发布了新的文献求助10
4秒前
www完成签到,获得积分20
4秒前
矿泉水完成签到,获得积分10
4秒前
syvshc的应助被WUHAO采纳,获得10
4秒前
4秒前
5秒前
5秒前
yuan完成签到,获得积分10
5秒前
WangJ1018发布了新的文献求助10
5秒前
啊森完成签到 ,获得积分10
5秒前
5秒前
6秒前
7秒前
新楚完成签到 ,获得积分10
7秒前
科研通AI6.3的应助被开心德地采纳,获得10
8秒前
Drcai发布了新的文献求助10
8秒前
搞怪的老九的应助被荔枝采纳,获得10
8秒前
水煮电吹风的应助被荔枝采纳,获得10
8秒前
烊烊烊发布了新的文献求助10
9秒前
禾页完成签到,获得积分10
9秒前
10秒前
水牛完成签到,获得积分10
10秒前
小羊发布了新的文献求助10
10秒前
大个的应助被ubless607采纳,获得30
10秒前
动物园小科畜完成签到,获得积分10
10秒前
852的应助被小羊爱科研采纳,获得10
10秒前
bkagyin的应助被漂泊采纳,获得10
11秒前
zzc完成签到,获得积分10
11秒前
11秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8187835
求助须知:如何正确求助?哪些是违规求助? 9575825
关于积分的说明 21843558
捐赠科研通 7785715
什么是DOI,文献DOI怎么找? 3435125
关于科研通互助平台的介绍 2559495
邀请新用户注册赠送积分活动 2482008